The VICC.ORG Directory of Cancers: Treatments, Services & Resources
Skin Cancers and Melanoma
The melanoma program comprises of a diverse group of clinical and laboratory scientists with one common goal: Advancement of the treatment of melanoma.
Skin Cancer
Clinical Trials for Skin Cancers and Melanoma
16 Open Trials
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | VICCMEL12109 05/17/2013 | A Phase III, Double-Blinded, Placebo-Controlled Study of Vemurafenib versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAFV600 Mutation-Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma |
| Therapeutic | VICCMEL1290 02/06/2013 | Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination with Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma |
| Therapeutic | VICCMEL12100 01/18/2013 | A Randomized, Open-Label Phase 3 Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy. |
| Therapeutic | VICCMEL1256 12/06/2012 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Vemurafenib (RO5185426) Adjuvant Therapy In Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma At High Risk For Recurrence |
| Therapeutic | VICCPHI1231 11/19/2012 | Phase 1/2 Study of PI-3K Inhibition with PX-866 Combined with Vemurafenib (BRAF Inhibitor) in Patients with BRAF-Mutant Cancer Including Advanced Melanoma |
| Therapeutic | VICCMEL1168 07/12/2012 | An Open-label Multicenter Phase II Study of Continuous Oral Vemurafenib in Patients with Locally-Advanced, Unresectable, Stage IIIC or Metastatic Melanoma and Activating Exon 15 BRAF mutations other than V600E |
| Therapeutic | VICCMD1188 06/08/2012 | An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers |
| Therapeutic | VICCMEL1130 02/08/2012 | An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment with OncoVEXGM-CSF or GM-CSF for Eligible Melanoma Patients Participating in Study 005/05 |
| Therapeutic | VICCMEL1036 10/24/2011 | A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients with Unresectable Stage III or Stage IV Melanoma Disease |
| Therapeutic | ECOGMELE1609 09/08/2011 | A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma |
| Therapeutic | VICCMEL0759 08/01/2008 | A Phase II Study of SU011248 in patients with metastatic mucosal or acral/lentiginous melanoma |
| Correlative | VICCMEL1081 09/28/2011 | The High-Dose Aldesleukin (IL-2) "Select" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High Dose IL-2 Treatment in Patients with Advanced Melanoma |
| Correlative | VICCMEL0287 05/06/2003 | Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository |
| Epidemiology, Observation, Outcomes | VICCMEL12117 02/18/2013 | A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY?) as First-Line Therapy |
| Screen, Detect, Diagnose | VICCMD1286 12/17/2012 | Screening Protocol to Detect BRAF V600 Mutation Positive Patients for Enrollment into Clinical Research Studies of Vemurafenib |
| Screen, Detect, Diagnose | VICCMEL09109 06/03/2010 | Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
